AJP - Regu Ad Instruments
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Regul Integr Comp Physiol 274: R1511-R1517, 1998;
0363-6119/98 $5.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chen, S.
Right arrow Articles by Chen, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chen, S.
Right arrow Articles by Chen, D.
Vol. 274, Issue 6, R1511-R1517, June 1998

Early captopril treatment prevents hypertrophydependent gene expression in hearts of SHR

Songcang Chen1, Jinzi Su2, Kegui Wu2, Wenyang Hu2, David G. Gardner1, and Daguang Chen2

2 Institute of Hypertension, First Affiliated Hospital, Fujian Medical University, Fuzhou 350005, People's Republic of China; and 1 Metabolic Research Unit and Department of Medicine, University of California at San Francisco, San Francisco, California 94143

Treatment of spontaneously hypertensive rats (SHR) with captopril (100 mg · kg-1 · day-1) throughout development and during the first 16 wk of life leads to a reduction in blood pressure and left ventricular hypertrophy. Blood pressures and hypertrophy are reduced in these animals (vs. untreated SHR) for up to 24 wk after discontinuation of the drug. We used conventional blot hybridization and Western analysis to examine hypertrophy-dependent gene expression during this period. Ventricular expression of the atrial natriuretic peptide gene was reduced by >90% at 16 wk of age in the captopril-treated SHR. Expression increased in the 24 wk after discontinuation of treatment, but remained well below that of the untreated SHR. A similar reduction in ventricular c-myc gene expression was seen with captopril treatment. Neither renal expression of the atrial natriuretic peptide gene nor ventricular expression of the c-fos gene was affected by captopril. This study demonstrates that captopril treatment during a critical period of development in the SHR leads to a sustained reduction in hypertrophy-dependent myocardial gene expression, which does not revert to levels seen in the untreated SHR after discontinuation of the drug.

atrial natriuretic peptide; cardiac hypertrophy; spontaneously hypertensive rat


This article has been cited by other articles:


Home page
J. Appl. Physiol.Home page
E. H. Schlenker, C. K. Kost Jr., and M. M. Likness
Effects of long-term captopril and L-arginine treatment on ventilation and blood pressure in obese male SHHF rats
J Appl Physiol, September 1, 2004; 97(3): 1032 - 1039.
[Abstract] [Full Text] [PDF]


Home page
Physiol. Rev.Home page
J. Zicha and J. Kunes
Ontogenetic Aspects of Hypertension Development: Analysis in the Rat
Physiol Rev, October 1, 1999; 79(4): 1227 - 1282.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online